TY - JOUR
T1 - Imaging bacteria with radiolabelled probes
T2 - Is it feasible?
AU - Signore, Alberto
AU - Artiko, Vera
AU - Conserva, Martina
AU - Ferro-Flores, Guillermina
AU - Welling, Mick M.
AU - Jain, Sanjay K.
AU - Hess, Søren
AU - Sathekge, Mike
N1 - Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/8
Y1 - 2020/8
N2 - Bacterial infections are the main cause of patient morbidity and mortality worldwide. Diagnosis can be difficult and delayed as well as the identification of the etiological pathogen, necessary for a tailored antibiotic therapy. Several non-invasive diagnostic procedures are available, all with pros and cons. Molecular nuclear medicine has highly contributed in this field by proposing several different radiopharmaceuticals (antimicrobial peptides, leukocytes, cytokines, antibiotics, sugars, etc.) but none proved to be highly specific for bacteria, although many agents in development look promising. Indeed, factors including the number and strain of bacteria, the infection site, and the host condition, may affect the specificity of the tested radiopharmaceuticals. At the Third European Congress on Infection/Inflammation Imaging, a round table discussion was dedicated to debate the pros and cons of different radiopharmaceuticals for imaging bacteria with the final goal to find a consensus on the most relevant research steps that should be fulfilled when testing a new probe, based on experience and cumulative published evidence.
AB - Bacterial infections are the main cause of patient morbidity and mortality worldwide. Diagnosis can be difficult and delayed as well as the identification of the etiological pathogen, necessary for a tailored antibiotic therapy. Several non-invasive diagnostic procedures are available, all with pros and cons. Molecular nuclear medicine has highly contributed in this field by proposing several different radiopharmaceuticals (antimicrobial peptides, leukocytes, cytokines, antibiotics, sugars, etc.) but none proved to be highly specific for bacteria, although many agents in development look promising. Indeed, factors including the number and strain of bacteria, the infection site, and the host condition, may affect the specificity of the tested radiopharmaceuticals. At the Third European Congress on Infection/Inflammation Imaging, a round table discussion was dedicated to debate the pros and cons of different radiopharmaceuticals for imaging bacteria with the final goal to find a consensus on the most relevant research steps that should be fulfilled when testing a new probe, based on experience and cumulative published evidence.
KW - Bacteria
KW - Infection
KW - Molecular imaging
KW - Nuclear medicine
KW - Radiopharmaceutical
UR - http://www.scopus.com/inward/record.url?scp=85100517174&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100517174&partnerID=8YFLogxK
U2 - 10.3390/jcm9082372
DO - 10.3390/jcm9082372
M3 - Article
C2 - 32722355
AN - SCOPUS:85100517174
SN - 2077-0383
VL - 9
SP - 1
EP - 10
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
IS - 8
M1 - 2372
ER -